Hodgkin lymphoma: does vitamin D deficiency affect outcomes?

  • Borchmann S & al.
  • J Clin Oncol
  • 17 Oct 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with Hodgkin lymphoma (HL), baseline vitamin D deficiency was significantly associated with inferior long-term tumor control and OS.

Why this matters

  • Vitamin D deficiency has been linked to the incidence of several cancers, but has not previously been evaluated with regard to HL.

Study design

  • Study to investigate associations between pretreatment vitamin D levels and outcomes in 351 first-line patients from the German Hodgkin Study Group clinical trials (HD7, HD8, and HD9).
  • Vitamin D deficiency was defined as 25-hydroxyvitamin D
  • Funding: None disclosed.

Key results

  • 50% of treatment-naive patients were vitamin D deficient at baseline.
  • 68% of patients with relapsed/refractory disease had baseline vitamin D deficiency vs 41% of relapse-free control individuals (P<.001>
  • Significantly inferior PFS with baseline vitamin D deficiency vs with sufficient or insufficient levels:
    • 5-year difference: 10.2% (95% CI, 0.8%-19.6%).
    • 10-year difference: 17.6% (95% CI, 6.9%-28.4%); HR, 2.13 (95% CI, 1.84-2.48; P<.001>
  • Significantly inferior OS with baseline vitamin D deficiency vs with sufficient or insufficient levels:
    • 5-year difference: 2.0% (95% CI, −5.3% to 9.3%).
    • 10-year difference: 11.1% (95% CI, 2.1%-20.2%); HR, 1.82 (95% CI, 1.53-2.15; P<.001>

Limitations

  • Retrospective data.